Atara Biotherapeutics Net Income
| ATRA Stock | USD 4.98 0.10 2.05% |
As of the 11th of February 2026, Atara Biotherapeutics shows the mean deviation of 5.63, and Risk Adjusted Performance of (0.05). Atara Biotherapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
Atara Biotherapeutics Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 0.2533 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -76.9 M | -80.7 M | |
| Net Loss | -76.9 M | -80.7 M | |
| Net Loss | -205.5 M | -215.7 M | |
| Net Loss | (10.26) | (10.78) | |
| Net Income Per E B T | 1.15 | 1.09 |
Atara | Net Income | Build AI portfolio with Atara Stock |
Analyzing Atara Biotherapeutics's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing Atara Biotherapeutics's current valuation and future prospects.
Latest Atara Biotherapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Atara Biotherapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Atara Biotherapeutics financial statement analysis. It represents the amount of money remaining after all of Atara Biotherapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Atara Biotherapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Atara Biotherapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (85.4 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Atara Net Income Regression Statistics
| Arithmetic Mean | (156,307,796) | |
| Coefficient Of Variation | (63.62) | |
| Mean Deviation | 86,472,614 | |
| Median | (123,300,000) | |
| Standard Deviation | 99,444,589 | |
| Sample Variance | 9889.2T | |
| Range | 312.1M | |
| R-Value | (0.29) | |
| Mean Square Error | 9665T | |
| R-Squared | 0.08 | |
| Significance | 0.26 | |
| Slope | (5,699,398) | |
| Total Sum of Squares | 158227.6T |
Atara Net Income History
Other Fundumenentals of Atara Biotherapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Atara Biotherapeutics Net Income component correlations
Atara Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Atara Biotherapeutics is extremely important. It helps to project a fair market value of Atara Stock properly, considering its historical fundamentals such as Net Income. Since Atara Biotherapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Atara Biotherapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Atara Biotherapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Atara Biotherapeutics. If investors know Atara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Atara Biotherapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share 2.86 | Revenue Per Share | Quarterly Revenue Growth (0.91) | Return On Assets | Return On Equity |
Understanding Atara Biotherapeutics requires distinguishing between market price and book value, where the latter reflects Atara's accounting equity. The concept of intrinsic value - what Atara Biotherapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Atara Biotherapeutics' price substantially above or below its fundamental value.
Understanding that Atara Biotherapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Atara Biotherapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Atara Biotherapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Atara Biotherapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Atara Biotherapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Atara Biotherapeutics.
| 11/13/2025 |
| 02/11/2026 |
If you would invest 0.00 in Atara Biotherapeutics on November 13, 2025 and sell it all today you would earn a total of 0.00 from holding Atara Biotherapeutics or generate 0.0% return on investment in Atara Biotherapeutics over 90 days. Atara Biotherapeutics is related to or competes with Ovid Therapeutics, Shattuck Labs, Context Therapeutics, MacroGenics, Champions Oncology, Oramed Pharmaceuticals, and Sutro Biopharma. Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer... More
Atara Biotherapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Atara Biotherapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Atara Biotherapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.08) | |||
| Maximum Drawdown | 73.72 | |||
| Value At Risk | (13.58) | |||
| Potential Upside | 8.7 |
Atara Biotherapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Atara Biotherapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Atara Biotherapeutics' standard deviation. In reality, there are many statistical measures that can use Atara Biotherapeutics historical prices to predict the future Atara Biotherapeutics' volatility.| Risk Adjusted Performance | (0.05) | |||
| Jensen Alpha | (0.85) | |||
| Total Risk Alpha | (1.73) | |||
| Treynor Ratio | (0.47) |
Atara Biotherapeutics February 11, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.05) | |||
| Market Risk Adjusted Performance | (0.46) | |||
| Mean Deviation | 5.63 | |||
| Coefficient Of Variation | (1,378) | |||
| Standard Deviation | 9.79 | |||
| Variance | 95.76 | |||
| Information Ratio | (0.08) | |||
| Jensen Alpha | (0.85) | |||
| Total Risk Alpha | (1.73) | |||
| Treynor Ratio | (0.47) | |||
| Maximum Drawdown | 73.72 | |||
| Value At Risk | (13.58) | |||
| Potential Upside | 8.7 | |||
| Skewness | (3.30) | |||
| Kurtosis | 16.82 |
Atara Biotherapeutics Backtested Returns
Atara Biotherapeutics secures Sharpe Ratio (or Efficiency) of -0.0955, which signifies that the company had a -0.0955 % return per unit of standard deviation over the last 3 months. Atara Biotherapeutics exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Atara Biotherapeutics' risk adjusted performance of (0.05), and Mean Deviation of 5.63 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 1.52, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Atara Biotherapeutics will likely underperform. At this point, Atara Biotherapeutics has a negative expected return of -0.95%. Please make sure to confirm Atara Biotherapeutics' value at risk, rate of daily change, and the relationship between the total risk alpha and kurtosis , to decide if Atara Biotherapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.56 |
Good reverse predictability
Atara Biotherapeutics has good reverse predictability. Overlapping area represents the amount of predictability between Atara Biotherapeutics time series from 13th of November 2025 to 28th of December 2025 and 28th of December 2025 to 11th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Atara Biotherapeutics price movement. The serial correlation of -0.56 indicates that roughly 56.0% of current Atara Biotherapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.56 | |
| Spearman Rank Test | -0.66 | |
| Residual Average | 0.0 | |
| Price Variance | 29.2 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Atara Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Atara Biotherapeutics reported net income of (85.4 Million). This is 125.02% lower than that of the Biotechnology sector and 221.92% lower than that of the Health Care industry. The net income for all United States stocks is 114.96% higher than that of the company.
Atara Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Atara Biotherapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Atara Biotherapeutics could also be used in its relative valuation, which is a method of valuing Atara Biotherapeutics by comparing valuation metrics of similar companies.Atara Biotherapeutics is currently under evaluation in net income category among its peers.
Atara Biotherapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Atara Biotherapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Atara Biotherapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Atara Biotherapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Atara Biotherapeutics that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Atara Biotherapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Atara Biotherapeutics' value.| Shares | Gsa Capital Partners Llp | 2025-06-30 | 19.6 K | Fmr Inc | 2025-06-30 | 17.2 K | Renaissance Technologies Corp | 2025-06-30 | 16.9 K | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 14.9 K | Bridgeway Capital Management, Llc | 2025-06-30 | 14 K | Northern Trust Corp | 2025-06-30 | 11.2 K | Ubs Group Ag | 2025-06-30 | 8.4 K | Bank Of America Corp | 2025-06-30 | 7.7 K | Royal Bank Of Canada | 2025-06-30 | 1.4 K | Ecor1 Capital, Llc | 2025-06-30 | 573.2 K | Redmile Group, Llc | 2025-06-30 | 441.7 K |
Atara Fundamentals
| Return On Equity | -20.15 | ||||
| Return On Asset | 0.31 | ||||
| Profit Margin | 0.15 % | ||||
| Operating Margin | (1.03) % | ||||
| Current Valuation | 38.48 M | ||||
| Shares Outstanding | 7.21 M | ||||
| Shares Owned By Insiders | 20.57 % | ||||
| Shares Owned By Institutions | 45.19 % | ||||
| Number Of Shares Shorted | 1.02 M | ||||
| Price To Earning | (4.50) X | ||||
| Price To Book | 1.97 X | ||||
| Price To Sales | 0.24 X | ||||
| Revenue | 128.94 M | ||||
| Gross Profit | 71.05 M | ||||
| EBITDA | (75.75 M) | ||||
| Net Income | (85.4 M) | ||||
| Cash And Equivalents | 331.31 M | ||||
| Cash Per Share | 3.51 X | ||||
| Total Debt | 43.83 M | ||||
| Debt To Equity | 0.29 % | ||||
| Current Ratio | 5.28 X | ||||
| Book Value Per Share | (5.08) X | ||||
| Cash Flow From Operations | (68.72 M) | ||||
| Short Ratio | 1.87 X | ||||
| Earnings Per Share | 2.86 X | ||||
| Target Price | 8.67 | ||||
| Number Of Employees | 38 | ||||
| Beta | -0.42 | ||||
| Market Capitalization | 35.91 M | ||||
| Total Asset | 109.1 M | ||||
| Retained Earnings | (2.05 B) | ||||
| Working Capital | (69.68 M) | ||||
| Current Asset | 324.6 M | ||||
| Current Liabilities | 9.71 M | ||||
| Net Asset | 109.1 M |
About Atara Biotherapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Atara Biotherapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Atara Biotherapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Atara Biotherapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Atara Biotherapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Atara Biotherapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Atara Biotherapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Atara Biotherapeutics Stock:Check out For information on how to trade Atara Stock refer to our How to Trade Atara Stock guide.You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Atara Biotherapeutics. If investors know Atara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Atara Biotherapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share 2.86 | Revenue Per Share | Quarterly Revenue Growth (0.91) | Return On Assets | Return On Equity |
Understanding Atara Biotherapeutics requires distinguishing between market price and book value, where the latter reflects Atara's accounting equity. The concept of intrinsic value - what Atara Biotherapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Atara Biotherapeutics' price substantially above or below its fundamental value.
Understanding that Atara Biotherapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Atara Biotherapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Atara Biotherapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.